These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12455769)

  • 21. Biomaterial-dependent blood activation during simulated extracorporeal circulation: a study of heparin-coated and uncoated circuits.
    Borowiec JW; Venge P; Henze A; Nilsson B; Stiernström H
    Thorac Cardiovasc Surg; 1997 Dec; 45(6):295-301. PubMed ID: 9477462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations.
    Videm V; Svennevig JL; Fosse E; Semb G; Osterud A; Mollnes TE
    J Thorac Cardiovasc Surg; 1992 Apr; 103(4):806-13. PubMed ID: 1548925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation.
    Wendel HP; Ziemer G
    Eur J Cardiothorac Surg; 1999 Sep; 16(3):342-50. PubMed ID: 10554855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Importance of uniform heparin coating on biopolymers.
    Da Luz Moreira P; Wada ML; Novello WP
    Artif Organs; 2000 Mar; 24(3):209-11. PubMed ID: 10759643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of three oxygenator-coated and one total-circuit-coated extracorporeal devices.
    Baksaas ST; Videm V; Pedersen T; Karlsen H; Mollnes TE; Brosstad F; Svennevig JL
    Perfusion; 1999 Mar; 14(2):119-27. PubMed ID: 10338323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation.
    Rinder CS; Rinder HM; Smith MJ; Tracey JB; Fitch J; Li L; Rollins SA; Smith BR
    J Thorac Cardiovasc Surg; 1999 Sep; 118(3):460-6. PubMed ID: 10469960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass.
    Fosse E; Moen O; Johnson E; Semb G; Brockmeier V; Mollnes TE; Fagerhol MK; Venge P
    Ann Thorac Surg; 1994 Aug; 58(2):472-7. PubMed ID: 8067851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of complement activation by soluble recombinant CR1 under conditions resembling those in a cardiopulmonary circuit: reduced up-regulation of CD11b and complete abrogation of binding of PMNs to the biomaterial surface.
    Larsson R; Elgue G; Larsson A; Ekdahl KN; Nilsson UR; Nilsson B
    Immunopharmacology; 1997 Dec; 38(1-2):119-27. PubMed ID: 9476123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparative studies of the adsorption behavior of plasma proteins to heparin-coated surfaces].
    Wendel HP; Weber N; Ziemer G
    Biomed Tech (Berl); 2000 Oct; 45(10):282-7. PubMed ID: 11085010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of the clotting system: heparin-coated versus non coated systems for extracorporeal circulation.
    Urlesberger B; Zobel G; Rödl S; Dacar D; Friehs I; Leschnik B; Muntean W
    Int J Artif Organs; 1997 Dec; 20(12):708-12. PubMed ID: 9506788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complement activation and bioincompatibility. The terminal complement complex for evaluation and surface modification with heparin for improvement of biomaterials.
    Mollnes TE; Videm V; Riesenfeld J; Garred P; Svennevig JL; Fosse E; Hogasen K; Harboe M
    Clin Exp Immunol; 1991 Oct; 86 Suppl 1(Suppl 1):21-6. PubMed ID: 1934602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of surface-bound and intravenously administered heparin on cell-surface interactions: inflammation and coagulation.
    Johnson G; Curry B; Cahalan L; Prater R; Biggerstaff J; Hussain A; Gartner M; Cahalan P
    Perfusion; 2013 May; 28(3):263-71. PubMed ID: 23401339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new in vitro model to study interaction between whole blood and biomaterials. Studies of platelet and coagulation activation and the effect of aspirin.
    Hong J; Nilsson Ekdahl K; Reynolds H; Larsson R; Nilsson B
    Biomaterials; 1999 Apr; 20(7):603-11. PubMed ID: 10208402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Artificial surface-induced cytokine synthesis: effect of heparin coating and complement inhibition.
    Lappegård KT; Fung M; Bergseth G; Riesenfeld J; Mollnes TE
    Ann Thorac Surg; 2004 Jul; 78(1):38-44; discussion 44-5. PubMed ID: 15223398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disparity in blood activation by two different heparin-coated cardiopulmonary bypass systems.
    Moen O; Fosse E; Brockmeier V; Andersson C; Mollnes TE; Høgåsen K; Venge P
    Ann Thorac Surg; 1995 Nov; 60(5):1317-23. PubMed ID: 8526620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment.
    Fukutomi M; Kobayashi S; Niwaya K; Hamada Y; Kitamura S
    Artif Organs; 1996 Jul; 20(7):767-76. PubMed ID: 8828766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heparin molecularly imprinted surfaces for the attenuation of complement activation in blood.
    Rosengren-Holmberg JP; Andersson J; Smith JR; Alexander C; Alexander MR; Tovar G; Ekdahl KN; Nicholls IA
    Biomater Sci; 2015 Aug; 3(8):1208-17. PubMed ID: 26222036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complement activation during cardiopulmonary bypass: effects of immobilized heparin.
    Pekna M; Hagman L; Haldén E; Nilsson UR; Nilsson B; Thelin S
    Ann Thorac Surg; 1994 Aug; 58(2):421-4. PubMed ID: 8067842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of heparin binding to the AN69 ST hemodialysis membrane: I. Preclinical studies.
    Chanard J; Lavaud S; Paris B; Toure F; Rieu P; Renaux JL; Thomas M
    ASAIO J; 2005; 51(4):342-7. PubMed ID: 16156296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Global and extended coagulation monitoring during extracorporeal lung assist with heparin-coated systems in ARDS patients.
    Gerlach M; Föhre B; Keh D; Riess H; Falke KJ; Gerlach H
    Int J Artif Organs; 1997 Jan; 20(1):29-36. PubMed ID: 9062829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.